Bryony Heath

Bryony Heath

Auto-generated profile, based on publicly available information

Bryony Heath

Scancell Ltd., Biodiscovery Institute, University of Nottingham, Nottingham, United Kingdom

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
FDForam Dave
Foram Dave
PVPoonam Vaghela
Poonam Vaghela
BHBryony Heath
Bryony Heath
ZDZuzana Dunster
Zuzana Dunster
EDElena Dubinina
Elena Dubinina
LDLindy Durrant
Lindy Durrant
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options. Fucosyl-GM1 (FucGM1) is a glycolipid overexpressed in the majority of SCLC tumors but virtually absent from normal healthy tissues. In this study, we validate a FucGM1-targeting T cell–redirecting bispecific (TCB) antibody for the treatment of SCLC. More than 80% of patient-derived xenograft tissues of SCLC expressed FucGM1, whereas only three normal human tissues: pituitary, thymus, and skin expressed low and focal FucGM1. A FucGM1-targeting TCB (SC134-TCB), based on the Fc-silenced humanized SC134 antibody, exhibited nanomolar efficiency in FucGM1 glycolipid and SCLC cell surface binding. SC134-TCB showed potent ex vivo killing of SCLC cell lines with donor-dependent EC50 ranging from 7.2 pmol/L up to 211.0 pmol/L, effectively activating T cells, with picomolar efficiency, coinciding with target-dependent cytokine production such as IFNγ, IL2, and TNFα and robust proliferation of both CD4 and CD8 T cells. The ex vivo SC134-TCB tumor controlling activity translated into an effective in vivo anti-DMS79 tumor therapy, resulting in 100% tumor-free survival in a human peripheral blood mononuclear cell admixed setting and 40% overall survival (55% tumor growth inhibition) with systemically administered human peripheral blood mononuclear cells. Combination treatment with atezolizumab further enhanced survival and tumor growth inhibition (up to 73%). A 10-fold SC134-TCB dose reduction maintained the strong in vivo antitumor impact, translating into 70% overall survival (P < 0.0001). Whole-blood incubation with SC134-TCB, as well as healthy human primary cells analysis, revealed no target-independent cytokine production. SC134-TCB presents an attractive candidate to deliver an effective immunotherapy treatment option for patients with SCLC.


17 June 2026
Verified
Other
Open access
FDForam Dave
Foram Dave
PVPoonam Vaghela
Poonam Vaghela
BHBryony Heath
Bryony Heath
ZDZuzana Dunster
Zuzana Dunster
EDElena Dubinina
Elena Dubinina
LDLindy Durrant
Lindy Durrant
Target-dependent multifunctional cytokine production